Dr. Reddy’s Laboratories announces the launch of Neostigmine Methylsulfate Injection, USP in the U.S. Market

By / 1 year ago / News Update / 312 Comments
Dr. Reddy’s Laboratories announces the launch of Neostigmine Methylsulfate Injection, USP in the U.S. Market

Mumbai, India and Princeton, NJ, USA. September 12, 2018— Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Neostigmine Methylsulfate Injection, USP, a therapeutic equivalent generic version of Bloxiverz (Neostigmine Methylsulfate) Injection approved by the U.S. Food and Drug Administration (USFDA).

The Bloxiverz brand and generic had U.S. sales of approximately $111 million MAT for the most recent twelve months ending in July 2018 according to IMS Health*.

Dr. Reddy’s Neostigmine Methylsulfate Injection, USP is available in 5 mg/10 mL and 10 mg/10 mL multi-dose vials.

 

admin

admin

The author didn't add any Information to his profile yet.

312 Comments

Leave a comment

Your email address will not be published. Required fields are marked. *